Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Priority Review Politics: With Two Pending DMD Products, FDA Still Faces Community Anxiety

Executive Summary

Duchenne muscular dystrophy advocates want updates on Sarepta's eteplirsen application; priority review for Marathon's deflazacort illuminates FDA's many considerations in agency’s ongoing effort to approve therapies for DMD.

Advertisement

Related Content

Marathon Gets Long-Known Duchenne Treatment On-Label, But Will Payers Respond?
Sarepta Pressured FDA On Eteplirsen Due To ‘Dire’ Finances, Gave Investors Rosier Picture
Keeping Track: Janssen Gets A Breakthrough Therapy Status, FDA Awards Two Orphan Drug Designations, Portola Lands A CRL
You Just Have To Wait: FDA Can't Hurry PDUFA VI Guidances
Marathon Looking To Go The Distance In DMD
FDA Finds Fault With Third Duchenne Muscular Dystrophy Drug Filing

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS118993

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel